NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
34 trialsNCT06173505 2026-03-13
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Phase 1/2 Terminated
NCT03386357 2026-03-12
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT05346484 2026-03-06
MAST
Imugene Limited
Phase 1 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03237572 2026-02-09
Breast-48
University of Virginia
Phase 1 Terminated
NCT06716853 2026-02-09
TEM-GU
Genenta Science
Phase 1/2 Terminated
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT05814666 2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2 Terminated
NCT03436056 2026-01-29
PRIMING
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04157517 2026-01-29
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
NCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT02819752 2026-01-21
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04799054 2026-01-20
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT05194072 2026-01-09
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04986852 2025-12-30
Olinvacimab With Pembrolizumab in Patients With mTNBC
PharmAbcine
Phase 2 Terminated
NCT06391775 2025-12-26
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
Phase 1/2 Terminated
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT05179603 2025-12-24
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
Phase 2 Terminated
NCT03225547 2025-12-23
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
Phase 2 Terminated